Research Progress of Targeted Therapy for BRAF Mutation
in Advanced Non-small Cell Lung Cancer / 中国肺癌杂志
Chinese Journal of Lung Cancer
; (12): 635-640, 2018.
Article
em Zh
| WPRIM
| ID: wpr-772389
Biblioteca responsável:
WPRO
ABSTRACT
Targeted therapy is one of the major treatment modalities in advanced non-small cell lung cancer (NSCLC) with sensitive driver gene mutations. BRAF is considered a promising oncogenic driver in NSCLC after the discovery of epidermal growth factor receptor (EGFR) mutation, anaplastic lymphoma kinase (ALK) fusion and ROS1 rearrangement. BRAF V600E mutation accounts for more than half of BRAF mutations, which is a potential therapeutic target for advanced NSCLC. This review aims to summarize the advancements of BRAF gene mutation and targeted therapy for BRAF mutation in NSCLC.
.
Palavras-chave
Texto completo:
1
Base de dados:
WPRIM
Assunto principal:
Patologia
/
Carcinoma Pulmonar de Células não Pequenas
/
Resistencia a Medicamentos Antineoplásicos
/
Proteínas Proto-Oncogênicas B-raf
/
Tratamento Farmacológico
/
Terapia de Alvo Molecular
/
Genética
/
Neoplasias Pulmonares
/
Métodos
/
Mutação
Limite:
Humans
Idioma:
Zh
Revista:
Chinese Journal of Lung Cancer
Ano de publicação:
2018
Tipo de documento:
Article